Literature DB >> 3549305

Characterization of insulin degradation by rat-liver low-density vesicles.

R J Pease, G D Smith, T J Peters.   

Abstract

When incubated in vitro, isolated rat liver low-density vesicles degrade endocytosed insulin intraluminally. The rate of intravesicular degradation suggests that this pathway contributes significantly to insulin degradation in vivo. The vesicles can be selectively disrupted with digitonin at concentrations that abolish the latency of NADH pyrophosphatase, with minimal effect on the cisternal Golgi marker, galactosyl transferase. The results suggest that latent NADH pyrophosphatase may act as a marker enzyme for the vesicles within which insulin is degraded. The possible role of insulin-glucagon protease, a candidate enzyme for insulin degradation by the liver, was investigated. The activity of latent insulin-glucagon protease associated with low-density vesicles is sufficient to account for the rate of intravesicular proteolysis. However, the rate of intravesicular proteolysis is insensitive to membrane-permeant thiol reagents under conditions which strongly inhibit insulin-glucagon protease. This shows that insulin-glucagon protease is not rate-limiting for insulin degradation by these vesicles, and is unlikely to be involved in the regulation of degradation. After disruption with Brij, internalized insulin remains associated with the membrane. Degradation is not inhibited by addition of excess unlabelled insulin to the medium, and occurs more rapidly than the degradation of an equal activity of iodo-insulin added to the disrupted membranes. This implies that degradation of endocytosed insulin occurs while it is still bound to the inner surface of the vesicles. When bacitracin is coinjected with iodo-insulin, it inhibits degradation of internalized insulin both by intact and Brij-disrupted vesicles, but not the degradation of added exogenous insulin, confirming that degradation is membrane-associated, and that it does not require the release of insulin into free solution.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3549305     DOI: 10.1111/j.1432-1033.1987.tb11018.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

Review 1.  Hepatic Insulin Clearance: Mechanism and Physiology.

Authors:  Sonia M Najjar; Germán Perdomo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

2.  Uptake and metabolic fate of [HisA8,HisB4,GluB10,HisB27]insulin in rat liver in vivo.

Authors:  F Authier; G M Di Guglielmo; G M Danielsen; J J Bergeron
Journal:  Biochem J       Date:  1998-06-01       Impact factor: 3.857

Review 3.  Physiological functions of endosomal proteolysis.

Authors:  T Berg; T Gjøen; O Bakke
Journal:  Biochem J       Date:  1995-04-15       Impact factor: 3.857

4.  The characterization of endosomal insulin degradation intermediates and their sequence of production.

Authors:  P J Seabright; G D Smith
Journal:  Biochem J       Date:  1996-12-15       Impact factor: 3.857

5.  Degradation of glucagon in isolated liver endosomes. ATP-dependence and partial characterization of degradation products.

Authors:  F Authier; B Desbuquois
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

Review 6.  Robert Feulgen Prize Lecture 1993. The journey of the insulin receptor into the cell: from cellular biology to pathophysiology.

Authors:  J L Carpentier
Journal:  Histochemistry       Date:  1993-09

7.  Chloroquine augments the binding of insulin to its receptor.

Authors:  A P Bevan; J R Christensen; J Tikerpae; G D Smith
Journal:  Biochem J       Date:  1995-11-01       Impact factor: 3.857

8.  Utilization of dietary glucose in the metabolic syndrome.

Authors:  Marià Alemany
Journal:  Nutr Metab (Lond)       Date:  2011-10-26       Impact factor: 4.169

9.  Selective degradation of insulin within rat liver endosomes.

Authors:  J J Doherty; D G Kay; W H Lai; B I Posner; J J Bergeron
Journal:  J Cell Biol       Date:  1990-01       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.